Literature DB >> 27825720

Ginsenoside Rd promotes non-amyloidogenic pathway of amyloid precursor protein processing by regulating phosphorylation of estrogen receptor alpha.

Xiaodong Yan1, Gengyao Hu2, Weiming Yan3, Tao Chen4, Feng Yang5, Xiao Zhang2, Gang Zhao6, Juanfang Liu7.   

Abstract

AIMS: Previous study demonstrated that Ginsenoside Rd. (GS-Rd) could improve cognitive and memory function in animal model of Alzheimer's disease. This study was aimed to investigate whether GS-Rd could improve non-amyloidogenic pathway by activating estrogen receptor (ER). MAIN
METHODS: 10mg/kg GS-Rd in ovariectomy (OVX)+GS-Rd group and equivalent volume of saline in sham operated group and OVX group were administrated intraperitoneally for two months, respectively. The Morris Water Maze was used to examine cognitive function of rats, with sAPPα and Aβ levels in the hippocampi measured. The culture medium of HT22 hippocampal neuronal cells were incubated with GS-Rd, ER antagonist ICI182.780, MAPK inhibitor PD98059, or PI3Kinhibitor LY294002, respectively. sAPPα levels was measured, and expression of α-secretase, sAPPα, β-secretase, Aβ, phosphorylation form of AKT (p-AKT), total AKT, p-ERK, total ERK, p-ERα, total ERα, p-ERβ and total ERβ were examined by Western blot to explore the estrogenic-like activity of GS-Rd. KEY
FINDINGS: GS-Rd attenuate cognitive and memory impairment, increased levels of sAPPα and reduced extracellular Aβ of OVX rats. In HT22, GS-Rd could upregulate sAPPα level, which can be inhibited by inhibitor of MAPK and PI3K pathway. In addition, inhibitor of estrogen receptor prevented GS-Rd triggered release of sAPPα and activation of MAPK and PI3K pathways. GS-Rd could increase expression of α-secretase and sAPPα, while decrease expression of β-secretase and Aβ. Besides, GS-Rd promoted phosphorylation of estrogen receptor alpha at Ser118 residue. SIGNIFICANCE: Our findings show that GS-Rd enhances learning and memory function of OVX rats by activating estrogen-like activity.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Amyloid-β precursor protein (APP) processing; Aβ; ER; GS-Rd; MAPK and PI3K pathway

Mesh:

Substances:

Year:  2016        PMID: 27825720     DOI: 10.1016/j.lfs.2016.11.002

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  14 in total

Review 1.  Better Bioactivity, Cerebral Metabolism and Pharmacokinetics of Natural Medicine and Its Advanced Version.

Authors:  Jiaxi Xie; Cailing Zhong; Tingting Wang; Dan He; Luyang Lu; Jie Yang; Ziyi Yuan; Jingqing Zhang
Journal:  Front Pharmacol       Date:  2022-06-27       Impact factor: 5.988

2.  Red Ginseng Inhibits Tau Aggregation and Promotes Tau Dissociation In Vitro.

Authors:  Soo Jung Shin; Yong Ho Park; Seong Gak Jeon; Sujin Kim; Yunkwon Nam; Sang-Muk Oh; Yong Yook Lee; Minho Moon
Journal:  Oxid Med Cell Longev       Date:  2020-06-30       Impact factor: 6.543

Review 3.  Active ginseng components in cognitive impairment: Therapeutic potential and prospects for delivery and clinical study.

Authors:  Md Jakaria; Md Ezazul Haque; Joonsoo Kim; Duk-Yeon Cho; In-Su Kim; Dong-Kug Choi
Journal:  Oncotarget       Date:  2018-09-11

Review 4.  Panax ginseng components and the pathogenesis of Alzheimer's disease (Review).

Authors:  Mayya Petrovna Razgonova; Valery Vyacheslavovich Veselov; Alexander Mikhailovich Zakharenko; Kirill Sergeyevich Golokhvast; Alexander Evgenyevich Nosyrev; Giancarlo Cravotto; Aristidis Tsatsakis; Demetrios A Spandidos
Journal:  Mol Med Rep       Date:  2019-02-19       Impact factor: 2.952

Review 5.  Panax ginseng and Panax quinquefolius: From pharmacology to toxicology.

Authors:  Cesare Mancuso; Rosaria Santangelo
Journal:  Food Chem Toxicol       Date:  2017-07-08       Impact factor: 6.023

6.  Preclinical systematic review of ginsenoside Rg1 for cognitive impairment in Alzheimer's disease.

Authors:  Hai-Yong Liang; Pei-Pei Zhang; Xi-Le Zhang; Yan-Yan Zheng; Yan-Ran Huang; Guo-Qing Zheng; Yan Lin
Journal:  Aging (Albany NY)       Date:  2021-03-03       Impact factor: 5.682

Review 7.  Neuroprotective Potentials of Panax Ginseng Against Alzheimer's Disease: A Review of Preclinical and Clinical Evidences.

Authors:  Jing Li; Qingxia Huang; Jinjin Chen; Hongyu Qi; Jiaqi Liu; Zhaoqiang Chen; Daqing Zhao; Zeyu Wang; Xiangyan Li
Journal:  Front Pharmacol       Date:  2021-06-02       Impact factor: 5.810

Review 8.  Panax ginseng as an adjuvant treatment for Alzheimer's disease.

Authors:  Hyeon-Joong Kim; Seok-Won Jung; Seog-Young Kim; Ik-Hyun Cho; Hyoung-Chun Kim; Hyewhon Rhim; Manho Kim; Seung-Yeol Nah
Journal:  J Ginseng Res       Date:  2018-01-12       Impact factor: 6.060

9.  Chinese Herbal Medicine Xueshuantong Enhances Cerebral Blood Flow and Improves Neural Functions in Alzheimer's Disease Mice.

Authors:  Yangmei Huang; Baihong Guo; Bihua Shi; Qingtao Gao; Qiang Zhou
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

10.  Enhancing α-secretase Processing for Alzheimer's Disease-A View on SFRP1.

Authors:  Bor Luen Tang
Journal:  Brain Sci       Date:  2020-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.